BioMarin Pharma (BMRN) Tops Q1 EPS by 43c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.64 +1.74%
EPS Growth %: -34.0%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -34.0%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $1.13, $0.43 better than the analyst estimate of $0.70. Revenue for the quarter came in at $745 million versus the consensus estimate of $741.02 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Taysha Gene Therapies (TSHA) PT Raised to $10 at BofA Securities
- H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
